UNASSIGNED: Stereotactic body radiotherapy (SBRT) shows promise in unresectable @entity788 , though this treatment modality has high rates of normal tissue @entity137 . This study explores the dosimetric utility of daily adaptive re-planning with pancreas SBRT. We used a previously developed supercomputing online re-planning environment (SCORE) to re-plan 10 @entity1 with pancreas SBRT. @entity5 and normal tissue contours were deformed from treatment planning computed tomographies (CTs) and transferred to daily cone-beam CT (CBCT) scans before re-optimizing each daily treatment plan. We compared the intended radiation dose, the actual radiation dose, and the optimized radiation dose for the @entity5 planning target volume ( @entity343 ) and the duodenum. Treatment re-optimization improved coverage of the @entity343 and reduced dose to the duodenum. Within the @entity343 , the actual hot spot (volume receiving 110% of the prescription dose) decreased from 4.5% to 0.5% after daily adaptive re-planning. Within the duodenum, the volume receiving the prescription dose decreased from 0.9% to 0.3% after re-planning. It is noteworthy that variation in the amount of air within a @entity1 * s stomach substantially changed dose to the @entity343 . Adaptive re-planning with pancreas SBRT has the ability to improve dose to the @entity5 and decrease dose to the nearby duodenum, thereby reducing the risk of @entity137 .

Dosimetric benefit of adaptive re-planning in XXXX stereotactic body radiotherapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatic cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'pancreas tumor'] @entity343 :: ('187978', 'Species') :: ['PTV']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic cancer']
